Kolon Life Science, Inc. (KOSDAQ: 102940), a subsidiary of the Kolon Group, is a leading Korean-based biochemical company focused on pharmaceutical ingredients and environmental biochemicals. Its pharmaceutical division provides active ingredients and intermediates ranging from zaltoprofen and flurbiprofen to argatroban and voglibose. In Asia, TissueGene has licensed intellectual property rights to Kolon Life Science (KLS) for commercialization of TG-C and TG-B. Through Kolon Life Science, TissueGene has been able to expedite commercialization of its products by conducting clinical trials in both the US and Korea. For more information, please visit http://www.kolonls.co.kr/english.